[{"address1": "4960 Peachtree Industrial Boulevard", "address2": "Suite 240", "city": "Norcross", "state": "GA", "zip": "30071", "country": "United States", "phone": "678 620 3186", "website": "https://galectintherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.", "fullTimeEmployees": 15, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joel  Lewis CPA", "age": 54, "title": "President, CEO & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 987039, "exercisedValue": 0, "unexercisedValue": 12600}, {"maxAge": 1, "name": "Mr. Jack W. Callicutt CPA", "age": 57, "title": "CFO, Treasurer & Corporate Secretary", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 572205, "exercisedValue": 0, "unexercisedValue": 9000}, {"maxAge": 1, "name": "Dr. Khurram  Jamil M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 547347, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Tritt J.D.", "title": "General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeff  Katstra", "title": "Head of CMC & Pharmaceutical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Beth  Knowles", "title": "Executive Assistant & Officer Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 3, "overallRisk": 5, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.64, "open": 4.7, "dayLow": 4.5925, "dayHigh": 4.88, "regularMarketPreviousClose": 4.64, "regularMarketOpen": 4.7, "regularMarketDayLow": 4.5925, "regularMarketDayHigh": 4.88, "payoutRatio": 0.0, "beta": 0.868, "forwardPE": -2.8571432, "volume": 193417, "regularMarketVolume": 193417, "averageVolume": 371885, "averageVolume10days": 530830, "averageDailyVolume10Day": 530830, "bid": 4.73, "ask": 4.87, "bidSize": 3, "askSize": 3, "marketCap": 307489280, "fiftyTwoWeekLow": 0.73, "fiftyTwoWeekHigh": 6.55, "fiftyDayAverage": 3.8632, "twoHundredDayAverage": 2.1152, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 417978272, "profitMargins": 0.0, "floatShares": 44985678, "sharesOutstanding": 64060262, "sharesShort": 7990039, "sharesShortPriorMonth": 7708146, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.1247, "heldPercentInsiders": 0.30079, "heldPercentInstitutions": 0.16455, "shortRatio": 30.1, "shortPercentOfFloat": 0.2076, "impliedSharesOutstanding": 64060262, "bookValue": -1.864, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -40457000, "trailingEps": -0.64, "forwardEps": -1.68, "lastSplitFactor": "1:6", "lastSplitDate": 1332460800, "52WeekChange": 0.7647059, "SandP52WeekChange": 0.1653893, "quoteType": "EQUITY", "currentPrice": 4.8, "targetHighPrice": 6.0, "targetLowPrice": 6.0, "targetMeanPrice": 6.0, "targetMedianPrice": 6.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 13771000, "totalCashPerShare": 0.215, "totalDebt": 122047000, "quickRatio": 1.278, "currentRatio": 1.432, "returnOnAssets": -0.98296, "freeCashflow": -27219124, "operatingCashflow": -35620000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "GALT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Galectin Therapeutics Inc.", "longName": "Galectin Therapeutics Inc.", "marketState": "CLOSED", "fiftyDayAverageChange": 0.93680024, "fiftyDayAverageChangePercent": 0.24249333, "twoHundredDayAverageChange": 2.6848001, "priceToBook": -2.5751073, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Galectin Therapeutics, Inc.", "nameChangeDate": "2025-09-19", "cryptoTradeable": false, "corporateActions": [], "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1031146200000, "postMarketChangePercent": 4.16458, "postMarketPrice": 4.9999, "postMarketChange": 0.1999, "regularMarketChange": 0.16, "regularMarketDayRange": "4.5925 - 4.88", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 371885, "fiftyTwoWeekLowChange": 4.07, "fiftyTwoWeekLowChangePercent": 5.5753427, "fiftyTwoWeekRange": "0.73 - 6.55", "fiftyTwoWeekHighChange": -1.75, "fiftyTwoWeekHighChangePercent": -0.26717556, "fiftyTwoWeekChangePercent": 76.47059, "earningsTimestampStart": 1754915400, "earningsTimestampEnd": 1755261000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.64, "epsForward": -1.68, "twoHundredDayAverageChangePercent": 1.269289, "postMarketTime": 1758326271, "regularMarketTime": 1758312002, "exchange": "NCM", "messageBoardId": "finmb_1065415", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.44828, "regularMarketPrice": 4.8, "displayName": "Galectin Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-20"}]